Dados B3 › ENJU3 × RADL3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | ENJU3 | RADL3 | year |
|---|---|---|---|
| ROE | -5.4% | 18.9% | 2025 |
| ROIC | -19.4%! | 24.8% | 2025 |
| ROA | -3.8% | 5.5% | 2025 |
| Gross margin | 55.7% | 29.3% | 2025 |
| EBIT margin | -11.0% | 6.2% | 2025 |
| Net margin | -6.4% | 2.9% | 2025 |
| Net debt/EBITDA | -21.86x | 0.69x | 2025 |
| Current ratio | 2.47x | 1.46x | 2025 |
| Revenue growth (1y) | -0.5% | 13.8% | 2025 |
| Revenue growth (5y CAGR) | 27.1% | 17.1% | 2025 |
| Piotroski F-Score | 4/9 | 5/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | ENJU3 | RADL3 | year |
|---|---|---|---|
| P/E | -13.92x | 32.24x | 2025 |
| P/B | 0.77x | 5.71x | 2025 |
| EV/EBITDA | 0.54x | 9.37x | 2025 |
| FCF yield | 0.2% | 2.5% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:12 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it